Lung Cancer Drug Candidate Showed Early Promise in Trial
Patients with specific mutations experienced tumor shrinkage and disease control in a preliminary study.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies effectively balance drug development costs with patient access?
Voronoi has reported promising Phase 1 clinical trial results for its lung cancer drug candidate, VRN11. The findings offer potential hope for patients with specific C797S mutations as the company works toward its goal of FDA accelerated approval by 2028.
Why it matters
The development represents a potential new treatment pathway for patients with advanced lung cancer, particularly those who have developed resistance to existing therapies. Achieving this milestone is critical for the company as it seeks to manage rising research costs and operational losses.
In a Phase 1 clinical trial, six patients receiving doses of 160 mg or higher of VRN11 achieved a 100% objective response rate. The study observed a 11-month median progression-free survival among these participants, though findings remain preliminary.
The players
Voronoi
A pharmaceutical company developing targeted cancer therapies, including candidates for lung cancer with specific genetic mutations.
The details
VRN11 is designed to target specific C797S mutations that often emerge in lung cancer, helping to control tumors even when they have spread to the brain. During the trial, investigators administered doses ranging from 160 mg to 480 mg to evaluate how effectively the drug shrinks tumors and delays disease progression. The trial has demonstrated significant intracranial disease control for patients with brain metastases, marking a focus on these high-risk cases.
Timeline
May 2026: Trial data was presented at the ASCO meeting.
First half of 2026: R&D expenses reached 41.7 billion Korean won.
Early September 2026: The company withdrew its clinical trial application in Canada.
2027-2028: Targeted window for FDA accelerated approval.
Health Landscape
The development of VRN11 reflects the ongoing industry focus on precision oncology for drug-resistant mutations. It must now navigate the clinical trial requirements necessary to secure FDA accelerated approval, a path essential for new treatments entering a competitive global market.
These findings are early-stage, meaning the drug is not yet available for clinical use or prescription. Patients with lung cancer who have questions about emerging trial options for resistant mutations should have a conversation with their oncologist.
The takeaway
Early data for VRN11 shows potential in treating lung cancer with specific genetic mutations. Patients should continue to track progress through their physicians and remain updated on clinical trial opportunities that may become available for their specific disease profile.
Further reading
Learn more about the latest innovations in clinical research on our Cancer hub.
Source note: This article includes information reported by 조선일보.
Live Poll
Do you trust that pharmaceutical companies effectively balance drug development costs with patient access?
